The company has market cap of $10.22 billion. Sumitomo Mitsui Asset Management Limited invested in 99,569 shares or 0.14% of the stock. The shares were purchased at an average price of $102.89. Amgen, Inc. (NASDAQ:AMGN) has risen 5.27% since August 28, 2016 and is uptrending. It has underperformed by 46.26% the S&P500. In the last 90 days, insiders have sold 266,299 shares of company stock worth $28,364,633. The biopharmaceutical company reported ($1.94) EPS for the quarter, beating the consensus estimate of ($1.97) by $0.03.
Gilead shares had fallen almost 8 percent in the 12 months that ended last week, as investors anxious that the company had not found a suitable addition to its product pipeline. The stock rose 1.68% or $1.24 reaching $75.03. Gilead Sciences Inc Com now has $96.36B valuation. It has outperformed by 38.77% the S&P500. BUTITTA CYNTHIA M also sold $2.86M worth of Kite Pharma Inc (NASDAQ:KITE) shares. (NASDAQ:GILD) shares with value of $325,114 were sold by Alton Gregg H.
Perhaps Monday's acquisition announcement from Gilead is just the first step in what could be a series of acquisitions that will enable it to build up its drug portfolio at a much faster pace.
Taylor Swift makes biggest YouTube debut ever with new music video
A snake ring wound around Swift's left ring finger - a nod to the imagery she's been using to tease her new album - looks to be the same piece Zoe Saldana wore to the 2013 Oscars.
The news was announced in a press release issued by both Gilead and Kite. More interesting news about Gilead Sciences, Inc. Bainco Intll Investors holds 8.77% of its portfolio in Kite Pharma Inc (NASDAQ:KITE) for 1.15 million shares. Its up 0.21, from 0.7 in 2016Q3. (NASDAQ:GILD). Moreover, Tdam Usa has 0.15% invested in Gilead Sciences, Inc. Monetary Mngmt Grp Incorporated owns 34,850 shares for 1.15% of their portfolio. (NASDAQ:GILD). One Natl Association has 19,735 shares for 0.11% of their portfolio. Assetmark Inc accumulated 0.01% or 9,492 shares. (NASDAQ:GILD) shares were sold by Cogan John Francis. $236,627 worth of Tristate Capital Holdings Inc (NASDAQ:TSC) was bought by Casey Helen Hanna on Tuesday, May 30. Carret Asset Mgmt Ltd Llc invested 0.26% in Gilead Sciences, Inc. (NASDAQ:GILD). 149,012 were reported by Scotia Cap Incorporated. The consensus target price is $74.18 with 6 brokers rating the stock a strong buy, 7 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell. Therefore 63% are positive. But Gilead was reportedly impressed by Kite's trial data. Jefferies maintained the shares of GILD in report on Monday, June 12 with "Buy" rating. Swiss National Bank increased its position in Gilead Sciences by 26.9% in the first quarter. As per Wednesday, February 3, the company rating was maintained by Credit Suisse. The stock has "Mkt Perform" rating by Leerink Swann on Tuesday, September 27. The rating was maintained by UBS on Friday, April 29 with "Buy". The firm earned "Buy" rating on Thursday, July 20 by Stephens. As per Wednesday, January 4, the company rating was downgraded by Bank of America. The firm has "Hold" rating given on Friday, November 13 by Standpoint Research. Canaccord Genuity has "Buy" rating and $9000 target.
Since March 2, 2017, it had 0 buys, and 6 sales for $2.28 million activity.
Investors sentiment decreased to 0.82 in 2016 Q4. Its up 0.02, from 0.91 in 2016Q3.
Trump Declines to Single Out Russia as Security Threat
Sater also claimed to have helped organize a 2006 trip to Moscow for Trump's daughter Ivanka Trump and son Jr. Trump, who was elected in November 2016, never went to Moscow, the newspaper said.
Institutional investors have recently modified their holdings of the company. 111 funds opened positions while 527 raised stakes. 125,600 are owned by Factory Mutual. Dimensional Fund Ltd Partnership invested in 0.01% or 598,939 shares. S Squared Ltd Liability Corp has 467,927 shares. Timothy L. Moore, EVP reported the sale of 6,000 shares. Next Finance owns 200 shares or 0% of their United States portfolio. Standpoint Research initiated it with "Buy" rating and $110 target in Wednesday, February 3 report. Tower Rech Capital (Trc) owns 1,575 shares. (NASDAQ:GILD). The New York-based Oppenheimer And has invested 2.22% in Gilead Sciences, Inc. (NASDAQ:AMGN) or 1,467 shares. Moore now owns $5,335,694 of the stock according to the SEC filing.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.
Cardinals trade Mike Leake to Mariners for prospect
Seattle also acquires cash and worldwide slot money while sending 21-year-old middle infield prospect Rayder Ascanio to St. Durability, however, might be Leake's best ability, particularly as he joins a Mariners rotation beset by injuries.